What is the Origin of SUSTAIN-6?

The term is an acronym assigned by the drug manufacturer to identify a specific trial within the broader SUmmary of Semaglutide Treatment And INtervention clinical program. The number "6" simply denotes its place in the sequence of trials. This nomenclature is standard practice in pharmaceutical clinical development.

What is the Mechanism of SUSTAIN-6?

The trial investigated semaglutide, which functions by mimicking the action of Glucagon-like Peptide-1 (GLP-1), an incretin hormone that enhances glucose-dependent insulin secretion and suppresses glucagon release. Beyond glycemic control, the study focused on the drug's effect on major adverse cardiovascular events. The mechanism involves improvements in blood pressure, lipid profiles, and reduced systemic inflammation, indicating broad metabolic benefits.

SUSTAIN-6

Meaning

A specific, phase 3, randomized, controlled, and double-blind clinical trial designed to investigate the cardiovascular safety and efficacy of the GLP-1 receptor agonist semaglutide in patients with type 2 diabetes. It is a landmark study providing crucial data on the drug’s systemic effects beyond glycemic control. The trial’s findings have significantly influenced clinical guidelines for diabetes management.